{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T07:50:41Z","timestamp":1773733841863,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>There have been numerous advancements in immune cell effector therapies in the malignant hematology space. This review article explores the pivotal studies that led to the approval of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and highlights available associated long-term and real-world data. It also examines the mechanisms of resistance and potential novel therapies to overcome these mechanisms.<\/jats:p>","DOI":"10.3389\/fonc.2026.1768614","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:26:19Z","timestamp":1773725179000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Review of advances in CAR-T therapies in malignant hematology"],"prefix":"10.3389","volume":"16","author":[{"given":"Neda","family":"Amirmokhtari","sequence":"first","affiliation":[{"name":"Hematologic malignancies and cellular therapy, The University of Kansas Hospital - Westwood Medical Pavilion","place":["Westwood, KS, United States"]},{"name":"Hematologic malignancies and cellular therapy, The University of Kansas Cancer Center Kansas City","place":["Kansas, KS, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Forat","family":"Lutfi","sequence":"additional","affiliation":[{"name":"Hematologic malignancies and cellular therapy, The University of Kansas Hospital - Westwood Medical Pavilion","place":["Westwood, KS, United States"]},{"name":"Hematologic malignancies and cellular therapy, The University of Kansas Cancer Center Kansas City","place":["Kansas, KS, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s1470-2045(21)00591-x","article-title":"Axicabtagene Ciloleucel in relapsed or refractory indolent non-hodgkin lymphoma (Zuma-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1182\/blood.2022018893","article-title":"5-year follow-up analysis from Zuma-5: A phase 2 trial of Axicabtagene Ciloleucel (axi-CEL) in patients with relapsed\/refractory indolent Non-Hodgkin lymphoma","volume":"144","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000967804.31464.ce","article-title":"S223: Real-world early outcomes of AXICABTAGENE Ciloleucel for relapsed or refractory follicular lymphoma","volume":"7","author":"Jacobson","year":"2023","journal-title":"HemaSphere"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 Elara trial","volume":"28","author":"Fowler","year":"2021","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.068","article-title":"Clinical outcomes of patients with relapsed\/refractory follicular lymphoma treated with tisagenlecleucel: Phase 2 Elara 3-year follow-up","volume":"30","author":"Schuster","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.856","article-title":"805mo real-world efficacy and safety of Tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French descar-T registry","volume":"35","author":"Bachy","year":"2024","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene Maraleucel in follicular lymphoma: The phase 2 transcend fl study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2024-198509","article-title":"Lisocabtagene Maraleucel (Liso-CEL) in patients (PTS) with relapsed or refractory (R\/R) follicular lymphoma (FL): Transcend FL 2-year follow-up","volume":"144","author":"Nastoupil","year":"2024","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01052-8","article-title":"Lisocabtagene Maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (transcend CLL 004): A multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1182\/blood-2024-200840","article-title":"Lisocabtagene Maraleucel (Liso-CEL) in patients (PTS) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (cll)\/small lymphocytic lymphoma (SLL): Updated follow-up of transcend CLL 004","volume":"144","author":"Siddiqi","year":"2024","journal-title":"Blood"},{"key":"B11","unstructured":"Bristol Myers Squibb - Bristol myers squibb presents First Data from the marginal zone lymphoma cohort of the transcend FL trial demonstrating deep and durable responses with Breyanzi (Lisocabtagene Maraleucel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene CILOLEUCEL car T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"5-year follow-up supports curative potential of Axicabtagene Ciloleucel in refractory large B-cell lymphoma (Zuma-1)","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116133","article-title":"Axicabtagene CILOLEUCEL as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2301665","article-title":"Survival with Axicabtagene Ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1182\/blood-2024-199139","article-title":"Real-world early outcomes of second-line Axicabtagene Ciloleucel (axi-CEL) therapy in patients (PTS) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of Tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (Juliet): A Multicentre, open-label, single-ARM, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116596","article-title":"Second-line Tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009890","article-title":"Real-world outcomes with Tisagenlecleucel in aggressive B-cell lymphoma: Subgroup analyses from the CIBMTR Registry","volume":"13","author":"Landsburg","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for patients with relapsed or refractory large B-cell lymphomas (transcend NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of Lisocabtagene Maraleucel in relapsed or refractory large B-cell lymphoma in transcend NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00339-4","article-title":"Lisocabtagene Maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for Haematopoietic Stem Cell Transplantation (pilot): An open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015262","article-title":"Lisocabtagene Maraleucel for R\/R LBCL in patients not intended for HSCT: Final results of the Phase 2 Pilot Study","volume":"9","author":"Sehgal","year":"2025","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00662-6","article-title":"Lisocabtagene Maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (transform): Results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00399","article-title":"Lisocabtagene Maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III transform study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene Maraleucel for relapsed\/refractory large B-cell lymphoma: A cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1914347","article-title":"KTE-X19 car T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the zuma-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015014","article-title":"Real-world outcomes of Brexucabtagene Autoleucel for relapsed or refractory mantle cell lymphoma: A CIBMTR analysis","volume":"9","author":"Ahmed","year":"2025","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02214","article-title":"Lisocabtagene Maraleucel in relapsed\/refractory mantle cell lymphoma: Primary analysis of the mantle cell lymphoma cohort from Transcend NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.319","article-title":"Lisocabtagene Maraleucel (Liso-CEL) in patients (PTS) with relapsed or refractory (R\/R) mantle cell lymphoma (MCL): Results from the final analysis of the MCL cohort of the open-label, phase 1, seamless design, Multicenter Transcend NHL 001 (transcend) study","volume":"31","author":"Wang","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00642","article-title":"Three-year update of Tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the Eliana trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015881","article-title":"Real-world data for Tisagenlecleucel in patients with R\/R B-all: Subgroup analyses from the CIBMTR Registry","volume":"9","author":"John","year":"2025","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, Multicentre Zuma-3 Study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02532-7","article-title":"Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in Zuma-3","volume":"39","author":"Shah","year":"2025","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2023-177693","article-title":"Real-world outcomes of Brexucabtagene Autoleucel (Brexu-cel) for relapsed or refractory (R\/R) adult B-cell acute lymphoblastic leukemia (B-cell ALL): Evidence from the CIBMTR Registry","volume":"142","author":"Bezerra","year":"2023","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2406526","article-title":"Obecabtagene Autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213614","article-title":"Ide-CEL or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024582","article-title":"IDE-CEL vs standard regimens in triple-class\u2013exposed relapsed and refractory multiple myeloma: Updated KARMMA-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01365","article-title":"Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: Real-world experience from the Myeloma Car T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (cartitude-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with Ciltacabtagene Autoleucel in cartitude-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2303379","article-title":"CILTA-CEL or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care Ciltacabtagene Autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/btt.s291768","article-title":"Armored car T-cells: The next chapter in T-Cell Cancer immunotherapy","volume":"15","author":"Hawkins","year":"2021","journal-title":"Biol: Targets Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2408771","article-title":"Enhanced car T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo car T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"Ebiomedicine"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic car-T cells in hematological Malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1155\/jimr\/5845167","article-title":"Advancements and future directions of dual\u2010target chimeric antigen receptor t\u2010cell therapy in preclinical and clinical studies","volume":"2025","author":"Zhang","year":"2025","journal-title":"J Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1768614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:26:21Z","timestamp":1773725181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1768614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":53,"alternative-id":["10.3389\/fonc.2026.1768614"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1768614","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"article-number":"1768614"}}